Comparative Pharmacology
Head-to-head clinical analysis: DURICEF versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURICEF versus VELOSEF 125.
DURICEF vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
500 mg to 1 g orally once or twice daily.
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic